<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>339</serviceExecutionTime><Drug id="90866"><DrugName>DS-1971</DrugName><DrugSynonyms><Name><Value>DS-1971a</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DS-1971</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1017506">Daiichi Sankyo Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1017506">Daiichi Sankyo Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1017506" type="Company"><TargetEntity id="4295880584" type="organizationId">Daiichi Sankyo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1295">Neuropathic pain</Indication><Indication id="20">Pain</Indication></IndicationsSecondary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-04T15:07:58.000Z</LastModificationDate><ChangeDateLast>2018-05-02T00:00:00.000Z</ChangeDateLast><AddedDate>2014-04-17T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017506" linkType="Company"&gt;Daiichi Sankyo&lt;/ulink&gt; was developing DS-1971 (DS-1971a), for the potential oral treatment of chronic pain [&lt;ulink linkID="1547326" linkType="Reference"&gt;1547326&lt;/ulink&gt;], [&lt;ulink linkID="1559248" linkType="Reference"&gt;1559248&lt;/ulink&gt;]. In March 2014, a phase I trial was initiated  [&lt;ulink linkID="1547326" linkType="Reference"&gt;1547326&lt;/ulink&gt;]. In October 2015, the drug was listed as being in phase I development [&lt;ulink linkID="1721196" linkType="Reference"&gt;1721196&lt;/ulink&gt;]; this was still the case in July 2017 [&lt;ulink linkID="1957259" linkType="Reference"&gt;1957259&lt;/ulink&gt;]. However, in April 2018, the program was discontinued from a strategic decision after a portfolio review [&lt;ulink linkID="2028294" linkType="Reference"&gt;2028294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously evaluating the drug for diabetic peripheral neuropathic pain. In January 2016, a phase II trial was expected to be initiated in February 2016; however, in July 2016, the study was withdrawn prior to enrollment due to the reassessment of phase II study indication [&lt;ulink linkID="1735339" linkType="Reference"&gt;1735339&lt;/ulink&gt;]. No development has been reported for some time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2016, a randomized, double-blind, placebo-controlled, parallel-group, phase II study (&lt;ulink linkID="258521" linkType="Protocol"&gt;JapicCTI-163193&lt;/ulink&gt;) to evaluate the efficacy and safety of DS-1971a in patients (expected n = 180) with pain caused by radiculopathy due to lumbar spinal stenosis, was  to begin in Japan. The study was expected to complete in March 2017 [&lt;ulink linkID="1757232" linkType="Reference"&gt;1757232&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a  phase II, randomized, double-blind, placebo- and active-controlled, parallel-group study (&lt;ulink linkID="253272" linkType="Protocol"&gt;NCT02673866&lt;/ulink&gt;; DS1971-A-U202) was expected to be initiated in February 2016, to evaluate the efficacy and safety of DS-1971 in patients (estimated n =  310) with diabetic peripheral neuropathic pain. At that time, the study was expected to complete in February 2017. In July 2016, the study was withdrawn prior to enrollment due to the reassessment of phase II study indication [&lt;ulink linkID="1735339" linkType="Reference"&gt;1735339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, a double-blind, randomized, placebo-controlled, parallel-assigned, phase I trial (&lt;ulink linkID="181042" linkType="Protocol"&gt;NCT02107885&lt;/ulink&gt;; DS1971-A-E101) was initiated to evaluate the safety, tolerability and pharmacokinetics of DS-1971a versus placebo in healthy male subjects (expected n = 64) in the UK. At that time, the trial was expected to complete in July 2014; in July 2014, the trial was completed  [&lt;ulink linkID="1547326" linkType="Reference"&gt;1547326&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-27T00:00:00.000Z</StatusDate><Source id="2028294" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-27T00:00:00.000Z</StatusDate><Source id="2028294" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-01-31T00:00:00.000Z</StatusDate><Source id="1735339" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1547326" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-09T00:00:00.000Z</StatusDate><Source id="1757232" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>